POL 509

Drug Profile

POL 509

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Polifarma
  • Class Oligopeptides; Pyrrolidinones; Small molecules
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Immunological disorders

Most Recent Events

  • 23 Jan 2017 Discontinued - Preclinical for Immunological disorders in Italy (unspecified route)
  • 09 Nov 2000 Suspended-Preclinical for Immunological disorders in Italy (Unknown route)
  • 21 Jul 1998 No-Development-Reported for Immunological disorders in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top